PL367133A1 - Sposób wytwarzania chiralnych diolosulfonów i dihydroksykwasów z grupy inhibitorów reduktazy HMG CoA - Google Patents
Sposób wytwarzania chiralnych diolosulfonów i dihydroksykwasów z grupy inhibitorów reduktazy HMG CoAInfo
- Publication number
- PL367133A1 PL367133A1 PL02367133A PL36713302A PL367133A1 PL 367133 A1 PL367133 A1 PL 367133A1 PL 02367133 A PL02367133 A PL 02367133A PL 36713302 A PL36713302 A PL 36713302A PL 367133 A1 PL367133 A1 PL 367133A1
- Authority
- PL
- Poland
- Prior art keywords
- coa reductase
- reductase inhibitors
- hmg coa
- dihydroxy acid
- preparing chiral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Pyridine Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29640301P | 2001-06-06 | 2001-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL367133A1 true PL367133A1 (pl) | 2005-02-21 |
Family
ID=23141867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02367133A PL367133A1 (pl) | 2001-06-06 | 2002-05-30 | Sposób wytwarzania chiralnych diolosulfonów i dihydroksykwasów z grupy inhibitorów reduktazy HMG CoA |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6875867B2 (pl) |
| EP (1) | EP1392656A4 (pl) |
| JP (1) | JP2004536813A (pl) |
| KR (1) | KR20040007657A (pl) |
| CN (1) | CN1656077A (pl) |
| BR (1) | BR0209942A (pl) |
| CA (1) | CA2449813A1 (pl) |
| CZ (1) | CZ20033329A3 (pl) |
| DE (1) | DE02737324T1 (pl) |
| ES (1) | ES2214169T1 (pl) |
| HU (1) | HUP0401724A2 (pl) |
| IL (1) | IL158525A0 (pl) |
| MX (1) | MXPA03011195A (pl) |
| PL (1) | PL367133A1 (pl) |
| TR (1) | TR200400600T3 (pl) |
| TW (1) | TWI256391B (pl) |
| WO (1) | WO2002098854A2 (pl) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110196039A9 (en) * | 1994-10-05 | 2011-08-11 | Kaesemeyer Wayne H | Controlled release arginine formulations |
| US6812345B2 (en) * | 2000-06-15 | 2004-11-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| ATE349431T1 (de) | 2001-07-13 | 2007-01-15 | Astrazeneca Uk Ltd | Herstellung von aminopyrimidinverbindungen |
| GB0211751D0 (en) * | 2002-05-22 | 2002-07-03 | Avecia Ltd | Compound and process |
| GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| UY28501A1 (es) * | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
| GB0321827D0 (en) * | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
| GB0514078D0 (en) * | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
| US7659281B2 (en) | 2006-04-25 | 2010-02-09 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors |
| US8455640B2 (en) * | 2006-05-03 | 2013-06-04 | Msn Laboratories Limited | Process for statins and its pharmaceutically acceptable salts thereof |
| ES2567171T3 (es) * | 2006-10-09 | 2016-04-20 | Msn Laboratories Private Limited | Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables |
| TW200831469A (en) * | 2006-12-01 | 2008-08-01 | Astrazeneca Uk Ltd | Chemical process |
| US8487105B2 (en) | 2009-01-19 | 2013-07-16 | Msn Laboratories Limited | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof |
| KR101157314B1 (ko) * | 2009-06-05 | 2012-06-15 | 주식회사종근당 | 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법 |
| US8987444B2 (en) | 2010-01-18 | 2015-03-24 | Msn Laboratories Private Limited | Process for the preparation of amide intermediates and their use thereof |
| WO2011104725A2 (en) | 2010-02-23 | 2011-09-01 | Cadila Healthcare Limited | Hmg-coa reductase inhibitors and process for the preparation thereof |
| WO2011121595A1 (en) * | 2010-04-01 | 2011-10-06 | Neuland Laboratories Ltd. | A process for the preparation of rosuvastatin calcium |
| CN102219780B (zh) * | 2010-04-14 | 2014-08-06 | 上海京新生物医药有限公司 | 制备(3r,5s,e)-7-(2-(n-甲基甲磺酰胺基)-4-(4-氟苯基)-6-异丙基-嘧啶-5-基)-2,2-二甲基-3,5-二氧六环-6-庚烯酸酯的方法 |
| AU2011243948B2 (en) * | 2010-04-23 | 2014-07-17 | Sun Pharmaceutical Industries Limited | Novel intermediates for the preparation of HMG-CoA reductase inhibitors |
| EP2665721B1 (en) | 2011-01-18 | 2015-07-08 | DSM Sinochem Pharmaceuticals Netherlands B.V. | Methyltetrazole sulfides and sulfones |
| ES2601479T3 (es) | 2011-01-18 | 2017-02-15 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Proceso para la preparación de diolsulfonas |
| EP2665723B1 (en) | 2011-01-18 | 2015-07-22 | DSM Sinochem Pharmaceuticals Netherlands B.V. | Process for the preparation of statins in the presence of base |
| CN102174039B (zh) * | 2011-03-10 | 2013-11-06 | 上海交通大学 | 高光学纯匹伐他汀钙关键中间体的制备方法 |
| WO2012140490A2 (en) | 2011-04-11 | 2012-10-18 | Aurobindo Pharma Limited | Process for preparing quinoline derivative |
| CN102816152B (zh) * | 2011-06-09 | 2015-09-09 | 上海京新生物医药有限公司 | 一种瑞苏伐他汀中间体的制备方法 |
| US9303001B2 (en) | 2011-07-19 | 2016-04-05 | Sunshine Lake Pharma Co., Ltd. | Intermediate of statin drugs and preparation thereof |
| WO2013083718A1 (en) | 2011-12-09 | 2013-06-13 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Process for the preparation of a statin precursor |
| EP2788341B1 (en) | 2011-12-09 | 2017-04-05 | DSM Sinochem Pharmaceuticals Netherlands B.V. | Process for the preparation of a thioprecursor for statins |
| CZ304171B6 (cs) * | 2011-12-16 | 2013-12-04 | Zentiva, K.S. | Zpusob prípravy chránených chirálních sulfon - diolu |
| WO2014108795A2 (en) | 2013-01-10 | 2014-07-17 | Aurobindo Pharma Limited | An improved process for the preparation of chiral diol sulfones and statins |
| CN103360384A (zh) * | 2013-07-30 | 2013-10-23 | 浙江京新药业股份有限公司 | HMG-CoA还原酶抑制剂关键中间体的合成方法 |
| CN103694228B (zh) * | 2013-12-18 | 2018-08-28 | 北京华禧联合科技发展有限公司 | 一种制备匹伐他汀钙关键中间体的方法 |
| WO2016125086A1 (en) * | 2015-02-03 | 2016-08-11 | Laurus Labs Private Limited | Processes for the preparation of rosuvastatin or pharmaceutically acceptable salts thereof |
| CN109574999B (zh) * | 2017-09-28 | 2022-03-08 | 安徽省庆云医药股份有限公司 | 一种匹伐他汀钙中间体的制备方法 |
| CN109574939B (zh) * | 2017-09-28 | 2022-05-27 | 安徽省庆云医药股份有限公司 | 一种瑞舒伐他汀钠的制备方法 |
| CN111518034A (zh) * | 2019-10-21 | 2020-08-11 | 山东理工职业学院 | 他汀类化合物及其中间体的制备方法 |
| CN112159403B (zh) | 2020-09-30 | 2022-04-15 | 复旦大学 | 一种用于合成他汀类药物的关键中间体的制备方法 |
| CN112679490A (zh) * | 2021-01-28 | 2021-04-20 | 安徽美诺华药物化学有限公司 | 瑞舒伐他汀钙含砜结构的手性侧链及其制备方法与用途 |
| CN114213350B (zh) * | 2021-12-29 | 2024-03-19 | 江苏福瑞康泰药业有限公司 | 一种他汀类药物中间体的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
-
2002
- 2002-05-30 PL PL02367133A patent/PL367133A1/pl not_active Application Discontinuation
- 2002-05-30 MX MXPA03011195A patent/MXPA03011195A/es active IP Right Grant
- 2002-05-30 JP JP2003501843A patent/JP2004536813A/ja not_active Withdrawn
- 2002-05-30 BR BR0209942-0A patent/BR0209942A/pt not_active IP Right Cessation
- 2002-05-30 CZ CZ20033329A patent/CZ20033329A3/cs unknown
- 2002-05-30 TR TR2004/00600T patent/TR200400600T3/xx unknown
- 2002-05-30 KR KR10-2003-7015967A patent/KR20040007657A/ko not_active Application Discontinuation
- 2002-05-30 IL IL15852502A patent/IL158525A0/xx unknown
- 2002-05-30 ES ES02737324T patent/ES2214169T1/es active Pending
- 2002-05-30 HU HU0401724A patent/HUP0401724A2/hu unknown
- 2002-05-30 CA CA002449813A patent/CA2449813A1/en not_active Abandoned
- 2002-05-30 US US10/158,355 patent/US6875867B2/en not_active Expired - Fee Related
- 2002-05-30 WO PCT/US2002/017269 patent/WO2002098854A2/en not_active Application Discontinuation
- 2002-05-30 DE DE0001392656T patent/DE02737324T1/de active Pending
- 2002-05-30 EP EP02737324A patent/EP1392656A4/en not_active Withdrawn
- 2002-05-30 CN CNA028109279A patent/CN1656077A/zh active Pending
- 2002-06-03 TW TW091111890A patent/TWI256391B/zh not_active IP Right Cessation
-
2005
- 2005-01-20 US US11/039,702 patent/US20050124641A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050124641A1 (en) | 2005-06-09 |
| IL158525A0 (en) | 2004-05-12 |
| DE02737324T1 (de) | 2004-07-15 |
| CN1656077A (zh) | 2005-08-17 |
| ES2214169T1 (es) | 2004-09-16 |
| KR20040007657A (ko) | 2004-01-24 |
| TR200400600T3 (tr) | 2004-06-21 |
| CZ20033329A3 (cs) | 2004-11-10 |
| MXPA03011195A (es) | 2004-03-18 |
| HUP0401724A2 (hu) | 2004-12-28 |
| CA2449813A1 (en) | 2002-12-12 |
| EP1392656A4 (en) | 2005-04-06 |
| JP2004536813A (ja) | 2004-12-09 |
| EP1392656A2 (en) | 2004-03-03 |
| WO2002098854A2 (en) | 2002-12-12 |
| US20030018199A1 (en) | 2003-01-23 |
| TWI256391B (en) | 2006-06-11 |
| BR0209942A (pt) | 2004-03-30 |
| WO2002098854A3 (en) | 2003-03-27 |
| US6875867B2 (en) | 2005-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL367133A1 (pl) | Sposób wytwarzania chiralnych diolosulfonów i dihydroksykwasów z grupy inhibitorów reduktazy HMG CoA | |
| AU2002346471A1 (en) | Process for the racemization of chiral quinazolinones | |
| HK1200368A1 (en) | Pharmaceutical compositions comprising a hmg coa reductase inhibitor hmg coa | |
| HK1121358A1 (en) | Biological information trend display and its method | |
| AP2004003189A0 (en) | Use of CETP inhibitors and optionally HMG COA reductase inhibitors and/or antihypertensive agents. | |
| PL374364A1 (pl) | Inhibitory CETP w kombinacji ze środkami przeciw nadciśnieniu i ich zastosowania | |
| AU5422099A (en) | Method for producing acrolein and/or acrylic acid from propane | |
| EP1286702A4 (en) | HMG COA REDUCTASE INHIBITORS TO PROMOTE ANGIOGENESIS | |
| AU2003245216A1 (en) | Surface modified stainless steel | |
| AU2003215107A1 (en) | Method of "wet-field" scanning | |
| AU2003271127A1 (en) | High-molecular aliphatic polyester and process for producing the same | |
| AU5512599A (en) | Method for producing acrolein and/or acrylic acid from propane | |
| AU5512699A (en) | Method for producing acrolein and/or acrylic acid from propane | |
| NO996206L (no) | Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer | |
| IL157597A0 (en) | Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors | |
| AU2002243922A1 (en) | Ap1 amine oxidase variants | |
| AU7608100A (en) | 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors | |
| AU2002248033A1 (en) | Process for producing n-formylamino acid and utilization thereof | |
| HUP0105145A3 (en) | Process for producing hmg-coa reductase inhibitor | |
| HUP0201597A3 (en) | Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines | |
| EP1375505A4 (en) | OPTICALLY ACTIVE ALKENYLPHOSPHINIC ACID ESTERS AND METHOD FOR THE PRODUCTION THEREOF | |
| PL337343A1 (en) | Method of obtaining drugs comprising inhibitors of hmg coa reductase | |
| HUP0105000A3 (en) | Process for producing hmg-coa reductase inhibitors | |
| FI20012552A (fi) | Metallikarbonaatin valmistusmenetelmä | |
| AU2003203174A1 (en) | Metal salts of (3s)-3-methoxycarbonyl-4-phenylbutyric acid and usage thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |